Global Early Cancer Screening for Dogs Market Strategic Research Report

Scope of the Report

The global Early Cancer Screening for Dogs market size is predicted to grow from US$ 208 million in 2025 to US$ 335 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.

Early cancer screening for dogs is a method of analyzing cancer-related biomarkers that may exist in dogs through blood, tissue or genetic testing, thereby discovering potential tumor risks when there are no obvious symptoms, helping to achieve early diagnosis and early treatment, and improving the cure rate and quality of life of dogs. It is an important preventive measure in the field of pet medicine.

The growth of the early canine cancer screening market is primarily driven by factors such as the aging pet dog population, an increase in breeds prone to cancer, heightened owner awareness regarding preventive healthcare, and continuous advancements in non-invasive testing technologies. As more families regard dogs as integral members of the household, owners are increasingly prioritizing extended lifespans, improved quality of life, and reduced burdens associated with treating advanced-stage cancer; this shift has moved cancer detection from post-symptomatic diagnosis toward routine screening for senior dogs, high-risk breeds, and seemingly healthy dogs. Meanwhile, the maturation of technologies—including blood biomarkers, circulating tumor DNA (ctDNA), molecular urine testing, genetic sequencing, and AI-driven imaging analysis—has made early screening more convenient, less invasive, and suitable for inclusion in annual wellness exams. The expansion of service networks by veterinary hospitals and reference laboratories, the gradual inclusion of advanced testing in pet insurance coverage, and rising pet healthcare expenditures have further stimulated market demand; however, factors such as testing sensitivity, the range of cancer types covered, service pricing, and the diagnostic pathway following a positive result continue to influence the pace of market adoption.

This report presents a comprehensive overview of the global Early Cancer Screening for Dogs market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Blood-based Screening
• Urine-based Screening
• Others

Segment by Coverage

• Multi-cancer Screening
• Single-cancer Screening
• Others

Segment by Category

• Small Dog
• Medium Sized Dog
• Large Dog

Segment by players, this report covers

• IDEXX Laboratories
• Antech Diagnostics
• VolitionRx
• Fujifilm
• Zoetis Diagnostics
• LABOKLIN
• NationWide Laboratories
• Midwest Vet Labs
• VDI Laboratory
• HT Vet
• Oncotect
• PETcision
• Bioguard Corporation
• CanCan Diagnostics

Segment by Application

• Routine Wellness Screening
• Senior and High-Risk Breed Screening
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Early Cancer Screening for Dogs market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Routine Wellness Screening, Senior and High-Risk Breed Screening, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact